title: Carboplatin and etoposide as outpatient treatment of advanced non-small-cell lung cancer.
abstract: Twenty-four outpatients with locally advanced (inoperable or unsuitable for radical radiotherapy) or metastatic non-small-cell lung cancer were treated with carboplatin (300 mg/m2 day 1)+etoposide (120 mg/2 day 1-3), every 3 weeks. Two patients died of disease progression before completing at least 2 cycles of chemotherapy. Four patients (16.7%) obtained a partial response, 10 had disease stabilization (41.7%) and 8 progressed (33.3%). Median overall survival was 8 months (range 1-22). Toxicity was moderate, with no nephro-, neuro- or ototoxicity.
authors.affiliation: Unità Operativa di Oncologia Medica, Ospedale S. Andrea, La Spezia, Italia.
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: M
authors.initials: M
authors.lastname: Landucci
authors.forename: F
authors.initials: F
authors.lastname: Vaira
authors.forename: A
authors.initials: A
authors.lastname: Vigani
authors.forename: G
authors.initials: G
authors.lastname: Bertelli
mesh_terms: D000368:Aged; D000553:Ambulatory Care; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
chemical_list: D005047:Etoposide; D016190:Carboplatin